Agios制药董事David Scadden报告减持普通股

华尔街洞察
16 Jul

Agios Pharmaceuticals Inc.董事David Scadden披露减持该公司普通股。具体交易细节可通过监管文件链接查阅。

本次持股变动信息源自美国证券交易委员会EDGAR系统(文件编号:0001439222-25-000084),由人工智能技术自动编译生成。该资讯仅供信息参考,不构成任何投资决策依据。上市公司Agios Pharmaceuticals, Inc.(AGIO)对原始文件内容承担全部责任。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10